Ultrasound enhanced prehospital thrombolysis using microbubbles infusion in patients with acute ST elevation myocardial infarction: Rationale and design of the Sonolysis study

Jeroen Slikkerveer, Pieter A. Dijkmans, Gertjan T. Sieswerda, Pieter A F M Doevendans, Arie P J van Dijk, Freek W A Verheugt, Thomas Richard Porter, Otto Kamp

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Experimental studies have shown that ultrasound contrast agents enhance the effectiveness of thrombolytic agents in the presence of ultrasound in vitro and in vivo. Recently, we have launched a clinical pilot study, called "Sonolysis", to study this effect in patients with ST-elevation myocardial infarction based on proximal lesions of the infarct-related artery. Methods/design: In our multicenter, randomized, placebo controlled clinical trial we will include patients between 18 and 80 years of age with their first ST-elevation myocardial infarction based on a proximal lesion of the infarct-related artery. After receiving a single bolus alteplase 50 mg IV (Actilyse® Boehringer Ingelheim GmbH), a loading dose of aspirin 500 mg, and heparin 5000 IU in the ambulance according to the prehospital thrombolysis protocol, patients, following oral informed consent, are randomized to undergo 15 minutes of pulsatile ultrasound with intravenous administration of ultrasound contrast agent or placebo without ultrasound. Afterwards coronary angiography and, if indicated, percutaneous coronary intervention will take place. A total of 60 patients will be enrolled in approximately 1 year. The primary endpoints are based on the coronary angiogram and consist of TIMI flow, corrected TIMI frame count, and myocardial blush grade. Follow-up includes 12-lead ECG, 2D-echocardiography, cardiac MRI, and enzyme markers to obtain our secondary endpoints, including the infarct size, wall motion abnormalities, and the global left ventricular function. Discussion: The Sonolysis study is the first multicenter, randomized, placebo controlled clinical trial investigating the therapeutic application of ultrasound and microbubbles in acute ST-elevation myocardial infarction patients. A positive finding may stimulate further research and technical innovations to implement the treatment in the ambulance and maybe obtain even more patency at an earlier stage.

Original languageEnglish (US)
Article number72
JournalTrials
Volume9
DOIs
StatePublished - Dec 10 2008

Fingerprint

Microbubbles
Ambulances
Placebos
Tissue Plasminogen Activator
Contrast Media
Randomized Controlled Trials
Arteries
Fibrinolytic Agents
Percutaneous Coronary Intervention
Coronary Angiography
Informed Consent
Left Ventricular Function
Intravenous Administration
Aspirin
Echocardiography
Heparin
Angiography
Electrocardiography
ST Elevation Myocardial Infarction
Enzymes

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

Slikkerveer, J., Dijkmans, P. A., Sieswerda, G. T., Doevendans, P. A. F. M., van Dijk, A. P. J., Verheugt, F. W. A., ... Kamp, O. (2008). Ultrasound enhanced prehospital thrombolysis using microbubbles infusion in patients with acute ST elevation myocardial infarction: Rationale and design of the Sonolysis study. Trials, 9, [72]. https://doi.org/10.1186/1745-6215-9-72

Ultrasound enhanced prehospital thrombolysis using microbubbles infusion in patients with acute ST elevation myocardial infarction : Rationale and design of the Sonolysis study. / Slikkerveer, Jeroen; Dijkmans, Pieter A.; Sieswerda, Gertjan T.; Doevendans, Pieter A F M; van Dijk, Arie P J; Verheugt, Freek W A; Porter, Thomas Richard; Kamp, Otto.

In: Trials, Vol. 9, 72, 10.12.2008.

Research output: Contribution to journalArticle

Slikkerveer, Jeroen ; Dijkmans, Pieter A. ; Sieswerda, Gertjan T. ; Doevendans, Pieter A F M ; van Dijk, Arie P J ; Verheugt, Freek W A ; Porter, Thomas Richard ; Kamp, Otto. / Ultrasound enhanced prehospital thrombolysis using microbubbles infusion in patients with acute ST elevation myocardial infarction : Rationale and design of the Sonolysis study. In: Trials. 2008 ; Vol. 9.
@article{9a7db31322d143499e56887ad2a7f985,
title = "Ultrasound enhanced prehospital thrombolysis using microbubbles infusion in patients with acute ST elevation myocardial infarction: Rationale and design of the Sonolysis study",
abstract = "Background: Experimental studies have shown that ultrasound contrast agents enhance the effectiveness of thrombolytic agents in the presence of ultrasound in vitro and in vivo. Recently, we have launched a clinical pilot study, called {"}Sonolysis{"}, to study this effect in patients with ST-elevation myocardial infarction based on proximal lesions of the infarct-related artery. Methods/design: In our multicenter, randomized, placebo controlled clinical trial we will include patients between 18 and 80 years of age with their first ST-elevation myocardial infarction based on a proximal lesion of the infarct-related artery. After receiving a single bolus alteplase 50 mg IV (Actilyse{\circledR} Boehringer Ingelheim GmbH), a loading dose of aspirin 500 mg, and heparin 5000 IU in the ambulance according to the prehospital thrombolysis protocol, patients, following oral informed consent, are randomized to undergo 15 minutes of pulsatile ultrasound with intravenous administration of ultrasound contrast agent or placebo without ultrasound. Afterwards coronary angiography and, if indicated, percutaneous coronary intervention will take place. A total of 60 patients will be enrolled in approximately 1 year. The primary endpoints are based on the coronary angiogram and consist of TIMI flow, corrected TIMI frame count, and myocardial blush grade. Follow-up includes 12-lead ECG, 2D-echocardiography, cardiac MRI, and enzyme markers to obtain our secondary endpoints, including the infarct size, wall motion abnormalities, and the global left ventricular function. Discussion: The Sonolysis study is the first multicenter, randomized, placebo controlled clinical trial investigating the therapeutic application of ultrasound and microbubbles in acute ST-elevation myocardial infarction patients. A positive finding may stimulate further research and technical innovations to implement the treatment in the ambulance and maybe obtain even more patency at an earlier stage.",
author = "Jeroen Slikkerveer and Dijkmans, {Pieter A.} and Sieswerda, {Gertjan T.} and Doevendans, {Pieter A F M} and {van Dijk}, {Arie P J} and Verheugt, {Freek W A} and Porter, {Thomas Richard} and Otto Kamp",
year = "2008",
month = "12",
day = "10",
doi = "10.1186/1745-6215-9-72",
language = "English (US)",
volume = "9",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Ultrasound enhanced prehospital thrombolysis using microbubbles infusion in patients with acute ST elevation myocardial infarction

T2 - Rationale and design of the Sonolysis study

AU - Slikkerveer, Jeroen

AU - Dijkmans, Pieter A.

AU - Sieswerda, Gertjan T.

AU - Doevendans, Pieter A F M

AU - van Dijk, Arie P J

AU - Verheugt, Freek W A

AU - Porter, Thomas Richard

AU - Kamp, Otto

PY - 2008/12/10

Y1 - 2008/12/10

N2 - Background: Experimental studies have shown that ultrasound contrast agents enhance the effectiveness of thrombolytic agents in the presence of ultrasound in vitro and in vivo. Recently, we have launched a clinical pilot study, called "Sonolysis", to study this effect in patients with ST-elevation myocardial infarction based on proximal lesions of the infarct-related artery. Methods/design: In our multicenter, randomized, placebo controlled clinical trial we will include patients between 18 and 80 years of age with their first ST-elevation myocardial infarction based on a proximal lesion of the infarct-related artery. After receiving a single bolus alteplase 50 mg IV (Actilyse® Boehringer Ingelheim GmbH), a loading dose of aspirin 500 mg, and heparin 5000 IU in the ambulance according to the prehospital thrombolysis protocol, patients, following oral informed consent, are randomized to undergo 15 minutes of pulsatile ultrasound with intravenous administration of ultrasound contrast agent or placebo without ultrasound. Afterwards coronary angiography and, if indicated, percutaneous coronary intervention will take place. A total of 60 patients will be enrolled in approximately 1 year. The primary endpoints are based on the coronary angiogram and consist of TIMI flow, corrected TIMI frame count, and myocardial blush grade. Follow-up includes 12-lead ECG, 2D-echocardiography, cardiac MRI, and enzyme markers to obtain our secondary endpoints, including the infarct size, wall motion abnormalities, and the global left ventricular function. Discussion: The Sonolysis study is the first multicenter, randomized, placebo controlled clinical trial investigating the therapeutic application of ultrasound and microbubbles in acute ST-elevation myocardial infarction patients. A positive finding may stimulate further research and technical innovations to implement the treatment in the ambulance and maybe obtain even more patency at an earlier stage.

AB - Background: Experimental studies have shown that ultrasound contrast agents enhance the effectiveness of thrombolytic agents in the presence of ultrasound in vitro and in vivo. Recently, we have launched a clinical pilot study, called "Sonolysis", to study this effect in patients with ST-elevation myocardial infarction based on proximal lesions of the infarct-related artery. Methods/design: In our multicenter, randomized, placebo controlled clinical trial we will include patients between 18 and 80 years of age with their first ST-elevation myocardial infarction based on a proximal lesion of the infarct-related artery. After receiving a single bolus alteplase 50 mg IV (Actilyse® Boehringer Ingelheim GmbH), a loading dose of aspirin 500 mg, and heparin 5000 IU in the ambulance according to the prehospital thrombolysis protocol, patients, following oral informed consent, are randomized to undergo 15 minutes of pulsatile ultrasound with intravenous administration of ultrasound contrast agent or placebo without ultrasound. Afterwards coronary angiography and, if indicated, percutaneous coronary intervention will take place. A total of 60 patients will be enrolled in approximately 1 year. The primary endpoints are based on the coronary angiogram and consist of TIMI flow, corrected TIMI frame count, and myocardial blush grade. Follow-up includes 12-lead ECG, 2D-echocardiography, cardiac MRI, and enzyme markers to obtain our secondary endpoints, including the infarct size, wall motion abnormalities, and the global left ventricular function. Discussion: The Sonolysis study is the first multicenter, randomized, placebo controlled clinical trial investigating the therapeutic application of ultrasound and microbubbles in acute ST-elevation myocardial infarction patients. A positive finding may stimulate further research and technical innovations to implement the treatment in the ambulance and maybe obtain even more patency at an earlier stage.

UR - http://www.scopus.com/inward/record.url?scp=58149506138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149506138&partnerID=8YFLogxK

U2 - 10.1186/1745-6215-9-72

DO - 10.1186/1745-6215-9-72

M3 - Article

C2 - 19068143

AN - SCOPUS:58149506138

VL - 9

JO - Trials

JF - Trials

SN - 1745-6215

M1 - 72

ER -